APPENDIX A – REMS

Initial REMS Approval: 06/10/2011 Most Recent Modification: XX/2011

NDA 22-345 POTIGA[™] (ezogabine) Tablets €

Drug Class: Anticonvulsant

GlaxoSmithKline LLC Corporation Service Company 2711 Centerville Road, Suite 400 Wilmington DE 19808

For correspondence (Authorized US Agent): 5 Moore Drive (MS 5.5222) Research Triangle Park, NC 27709-3398 919-483-3073 Fax: 919-315-8319

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL:

The goal of the REMS for POTIGA is to inform healthcare professionals of the risk of urinary retention and the symptoms of acute urinary retention in patients taking POTIGA.

II. REMS ELEMENTS

A. Communication Plan

For Healthcare Professionals

GlaxoSmithKline LLC (GSK) will implement a communication plan to support the implementation of this REMS that includes the following elements:

1. A Dear Healthcare Professional (HCP) Letter designed to disseminate information about the risk of urinary retention with POTIGA. Within the first four weeks of retail availability of POTIGA, and annually from that date for the next two years, the Dear Healthcare Professional (HCP) letters will be mailed to the following audiences:

- a. Prescribing physicians (i.e., Epileptologists, Neurologists and Neurosurgeons) and physicians who may evaluate and treat patients with possible urinary retention (i.e., Urologists and Emergency Room Physicians)
- b. Pharmacists dispensing POTIGA tablets and the Medication Guide

After the initial mailing, new prescribers of POTIGA will be included in subsequent mailings of the Dear HCP letter.

The mailing will include a copy of the Prescribing Information (PI) and the Medication Guide.

- 2. REMS Program Website
 - a. There are two ways that Healthcare Professionals (HCPs) can access the REMS Program information for POTIGA on the internet. The REMS Program website for HCPs will be accessed directly from the homepage for POTIGA (www.potiga.com) via the "for HCP" link. In addition, this page will automatically be shown when HCPs visit GSK's professional website portal www.gsksource.com and click on product information for POTIGA. This REMS Program information will be shown automatically, such that HCPs visiting the healthcare provider area of the website can view the REMS Program information prior to viewing other areas of the website. Included in the information will be a brief explanation of the REMS, the goal of the REMS for POTIGA, and separate links for downloadable versions of the full Prescribing Information, the Medication Guide, and the Dear HCP Letters. The webpage also includes the indication for POTIGA, Important Safety Information for Healthcare Professionals, and links to other product information for POTIGA.
 - b. The online information will be available to all healthcare professionals as it is in the public domain.

The following materials are part of the REMS and are attached:

- Dear Healthcare Professional Letter (Attachment A)
- Dear Pharmacist Letter (Attachment B)
- REMS Program website for healthcare professionals (Attachment C)

B. Timetable for Submission of Assessments

GSK will submit assessments of the REMS to FDA 1, 2, 3, and 7 years from the date of initial approval of the REMS (June 10, 2011).

To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date for that assessment.

GSK will submit each assessment so it will be received by the FDA on or before the due date.

ATTACHMENT A – Dear Healthcare Professional Letter – Physicians

IMPORTANT DRUG WARNING

Subject: Risk of Urinary Retention with POTIGA

Dear Healthcare Professional

The purpose of this letter is to inform you of important safety information for POTIGATM (ezogabine) Tablets , approved by the Food and Drug Administration (FDA) for adjunctive treatment of partial onset seizures in patients 18 years of age and older. As a potassium channel opener, POTIGA can reduce the contractility of urinary bladder smooth muscle which can cause urinary retention.

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for POTIGA to ensure the benefits of the drug outweigh the risk of urinary retention and its associated morbidities. As one element of the REMS, we are providing this letter to further communicate this risk.

<u>Risk of Urinary Retention</u>

POTIGA caused urinary retention in clinical trials. Urinary retention was reported in 29 of 1365 (approximately 2%) patients receiving POTIGA in open-label and placebo controlled epilepsy trials with 5 (17%) of these patients requiring catheterization for urinary retention. POTIGA was discontinued in 4 patients who required catheterization. Following discontinuation, these 4 patients were able to void spontaneously; however, 1 of the 4 patients continued intermittent self-catheterization. A fifth patient continued treatment with POTIGA and was able to void spontaneously after catheter removal. Hydronephrosis occurred in 2 patients, one of whom had associated renal function impairment that resolved upon discontinuation of POTIGA. Hydronephrosis was not reported in placebo patients. An assessment of a patient's risk of urinary retention, including medical history and concomitant medication use, should be made for all patients before initiating treatment with POTIGA.

The Prescribing Information for POTIGA states in the *Warnings and Precautions* section that because of the increased risk of urinary retention on POTIGA, urologic symptoms should be carefully monitored. Closer monitoring is recommended for patients who have other risk factors for urinary retention (e.g., benign prostatic hyperplasia [BPH]), patients who are unable to communicate clinical symptoms (e.g., cognitively impaired patients), or patients who use concomitant medications that may affect voiding (e.g., anticholinergics). In these patients, a comprehensive evaluation of urologic symptoms prior to and during treatment with POTIGA may be appropriate.

Prescribers should inform all patients that:

- POTIGA may cause urinary retention, including urinary hesitation and dysuria
- Patients should seek immediate medical attention if they experience any symptoms of urinary retention, are unable to urinate and/or have urinary pain

Urologists and Emergency Room Physicians may be asked to evaluate patients with respect to suitability for treatment with POTIGA or to evaluate and/or treat patients with potential urinary retention.

Medication Guide

A Medication Guide is available for POTIGA and contains important safety information for patients. Specifically, the Medication Guide includes information on symptoms of urinary retention described as being unable to start urinating, having trouble emptying the bladder, having a weak urine stream, or having pain with urination. The Medication Guide instructs patients to call their healthcare provider right away if they experience any of these symptoms.

Additional copies of the Medication Guide for POTIGA are available from:

- the toll-free medical information line at 1-888-825-5249
- an informational website for POTIGA: <u>www.potiga.com</u>

Reporting Adverse Events

If you become aware of an adverse event involving POTIGA please contact:

- GlaxoSmithKline at 1-800-334-4153 and/or
- FDA MedWatch program by phone at 1-800-FDA-1088 or online at <u>www.fda.gov/medwatch/report.htm</u>

This letter is not a comprehensive description of the risks with the use of POTIGA. Please read the accompanying full Prescribing Information and Medication Guide for a complete description of these risks.

ATTACHMENT B – Dear Healthcare Professional Letter – Pharmacist

IMPORTANT DRUG WARNING

Subject: Risk of Urinary Retention with POTIGA

Dear Pharmacist

The purpose of this letter is to inform you of important safety information for POTIGATM (ezogabine) Tablets , approved by the Food and Drug Administration (FDA) for adjunctive treatment of partial onset seizures in patients 18 years of age and older. As a potassium channel opener, POTIGA can reduce the contractility of urinary bladder smooth muscle which can cause urinary retention.

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for POTIGA to ensure the benefits of the drug outweigh the risk of urinary retention and its associated morbidities.

As one element of the REMS, we are providing this letter to further communicate these risks.

Risk of Urinary Retention

POTIGA caused urinary retention in clinical trials. The Prescribing Information for POTIGA states in the *Warnings and Precautions* section that because of the increased risk of urinary retention on POTIGA, urologic symptoms should be carefully monitored. Closer monitoring is recommended for patients who have other risk factors for urinary retention (e.g., benign prostatic hyperplasia [BPH]), patients who are unable to communicate clinical symptoms (e.g., cognitively impaired patients), or patients who use concomitant medications that may affect voiding (e.g., anticholinergics).

Patients should be informed that POTIGA may cause urinary retention (including urinary hesitation and dysuria). If patients experience any symptoms of urinary retention, inability to urinate, and/or pain with urination, they should be instructed to seek immediate medical assistance, as these symptoms may indicate possible acute urinary retention.

As a Pharmacist, you have a key role in communicating these risks by providing the Medication Guide with every prescription filled for POTIGA and counselling patients as appropriate.

Medication Guide

A Medication Guide is available for POTIGA and contains important safety information for patients. Specifically, the Medication Guide includes information on symptoms of urinary retention described as being unable to start urinating, having trouble emptying the bladder, having a weak urine stream, or having pain with urination. The Medication Guide instructs patients to call their healthcare provider right away if they experience any of these symptoms.

The Medication Guide will be attached to every bottle and enclosed in each sample pack of POTIGA. The label of each container or package of POTIGA will include a prominent instruction to dispensers to provide a Medication Guide, which is attached to the package. The instruction states "Dispense the accompanying Medication Guide to each patient."

Additional copies of the Medication Guide for POTIGA are available from:

- the toll-free medical information line at 1-888-825-5249
- an informational website for POTIGA: <u>www.potiga.com</u>

Reporting Adverse Events

If you become aware of an adverse event involving POTIGA please contact:

- GlaxoSmithKline at 1-800-334-4153and/or
- FDA MedWatch program by phone at 1-800-FDA-1088 or online at www.fda.gov/medwatch/report.htm

This letter is not a comprehensive description of the risks with the use of POTIGA. Please read the accompanying full Prescribing Information and Medication Guide for a complete description of these risks.

NDA 022345/S-001

FDA Approved Labeling Text dated 3/19/2012 Page 1

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use POTIGA safely and effectively. See full prescribing information for POTIGA.

POTIGA (ezogabine) Tablets, CV Initial U.S. Approval: 2011

-----INDICATIONS AND USAGE------

POTIGA is a potassium channel opener indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older. (1)

----- DOSAGE AND ADMINISTRATION ------

- Administer in 3 divided doses daily, with or without food. (2)
- The initial dosage should be 100 mg 3 times daily (300 mg per day) for 1 week. (2)
- Titrate to maintenance dosage by increasing the dosage at weekly intervals by no more than 150 mg per day. (2)
- Optimize effective dosage between 200 mg 3 times daily (600 mg per day) to 400 mg 3 times daily (1,200 mg per day). (2)
- In controlled clinical trials, 400 mg 3 times daily (1,200 mg per day) showed limited improvement compared to 300 mg 3 times daily (900 mg per day) with an increase in adverse reactions and discontinuations. (2)
- When discontinuing POTIGA, reduce the dosage gradually over a period of at least 3 weeks. (2, 5.6)
- Dosing adjustments are required for geriatric patients and patients with moderate to severe renal or hepatic impairment. (2)

---- DOSAGE FORMS AND STRENGTHS -----Tablets: 50 mg, 200 mg, 300 mg, and 400 mg. (3)

-----CONTRAINDICATIONS ------None. (4)

---- WARNINGS AND PRECAUTIONS-----

- Urinary retention: Patients should be carefully monitored for urologic symptoms. (5.1)
- Neuropsychiatric symptoms: Monitor for confusional state, psychotic

FULL PRESCRIBING INFORMATION: CONTENTS*

- INDICATIONS AND USAGE 1
- DOSAGE AND ADMINISTRATION 2
- **DOSAGE FORMS AND STRENGTHS** 3
- CONTRAINDICATIONS 4
- WARNINGS AND PRECAUTIONS 5
 - 5.1
 - Urinary Retention Neuro-Psychiatric Symptoms 5.2
 - **Dizziness and Somnolence** 5.3
 - **QT** Interval Effect 5.4
 - Suicidal Behavior and Ideation 55
 - 5.6 Withdrawal Seizures
- **ADVERSE REACTIONS** 6
- **Clinical Trials Experience** 6.1 7
- DRUG INTERACTIONS
- Antiepileptic Drugs 7.1
- Digoxin 7.2
- Alcohol 7.3
- Laboratory Tests 7.4
- **USE IN SPECIFIC POPULATIONS** 8
 - 8.1 Pregnancy
 - Labor and Delivery 8.2
 - 8.3 **Nursing Mothers**
 - Pediatric Use 84
 - 8.5 Geriatric Use
 - Patients With Renal Impairment 8.6
 - Patients With Hepatic Impairment 8.7

symptoms, and hallucinations. (5.2)

- Dizziness and somnolence: Monitor for dizziness and somnolence. (5.3)
- OT prolongation: OT interval should be monitored in patients taking concomitant medications known to increase the QT interval or with certain heart conditions. (5.4)
- Suicidal behavior and ideation: Monitor for suicidal thoughts or behaviors. (5.5)

---- ADVERSE REACTIONS ------

The most common adverse reactions (incidence $\geq 4\%$ and approximately twice placebo) are dizziness, somnolence, fatigue, confusional state, vertigo, tremor, abnormal coordination, diplopia, disturbance in attention, memory impairment, asthenia, blurred vision, gait disturbance, aphasia, dysarthria, and balance disorder. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-- DRUG INTERACTIONS ---

- Ezogabine plasma levels may be reduced by concomitant administration of phenytoin or carbamazepine. An increase in dosage of POTIGA should be considered when adding phenytoin or carbamazepine. (7.1)
- N-acetyl metabolite of ezogabine may inhibit renal clearance of digoxin, a P-glycoprotein substrate. Monitor digoxin levels. (7.2)

------ USE IN SPECIFIC POPULATIONS -------

- Pregnancy: Based on animal data, may cause fetal harm. Pregnancy registry available. (8.1)
- Pediatric use: Safety and effectiveness in patients under 18 years of age have not been established. (8.4)

See 17 for PATIENT COUNSELING INFORMATION and **MEDICATION GUIDE.**

Revised:

DRUG ABUSE AND DEPENDENCE q

- **Controlled Substance** 9.1
- Abuse 9.2
- Dependence 9.3
- 10 OVERDOSAGE
 - 10.1 Signs, Symptoms, and Laboratory Findings
- 10.2 Management of Overdose
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- **14 CLINICAL STUDIES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
 - 17.1 Urinary Retention
 - 17.2 Psychiatric Symptoms
 - 17.3 Central Nervous System Effects
 - 17.4 Suicidal Thinking and Behavior
 - 17.5 Pregnancy

*Sections or subsections omitted from the full prescribing information are not listed.

1 FULL PRESCRIBING INFORMATION

- 2 1 INDICATIONS AND USAGE
- POTIGATM is indicated as adjunctive treatment of partial-onset seizures in patients aged
 18 years and older.

5 2 DOSAGE AND ADMINISTRATION

6 The initial dosage should be 100 mg 3 times daily (300 mg per day). The dosage should 7 be increased gradually at weekly intervals by no more than 50 mg 3 times daily (increase in the 8 daily dose of no more than 150 mg per day) up to a maintenance dosage of 200 mg to 400 mg 3 9 times daily (600 mg to 1,200 mg per day), based on individual patient response and tolerability. 10 This information is summarized in Table 1 under General Dosing. In the controlled clinical trials, 11 400 mg 3 times daily showed limited evidence of additional improvement in seizure reduction, 12 but an increase in adverse events and discontinuations, compared to the 300 mg 3 times daily 13 dosage. The safety and efficacy of doses greater than 400 mg 3 times daily (1,200 mg per day) 14 have not been examined in controlled trials. 15 No adjustment in dosage is required for patients with mild renal or hepatic impairment 16 (see General Dosing, Table 1). Dosage adjustment is required in patients with moderate and 17 greater renal or hepatic impairment (see Dosing in Specific Populations, Table 1). 18 POTIGA should be given orally in 3 equally divided doses daily, with or without food.

- 19 POTIGA Tablets should be swallowed whole.
- 20 If POTIGA is discontinued, the dosage should be gradually reduced over a period of at
- 21 least 3 weeks, unless safety concerns require abrupt withdrawal.
- 22

23	Table 1. Dosing Recommendations
25	Tuble 1. Dobing Recommendations

Specific Population	Initial Dose	Titration	Maximum Dose
	General	Dosing	
General population	100 mg 3 times	Increase by no more	400 mg 3 times daily
(including patients with	daily	than 50 mg 3 times	(1,200 mg per day)
mild renal or hepatic	(300 mg per day)	daily, at weekly	
impairment)		intervals	
	Dosing in Specif	ic Populations	
Geriatrics	50 mg 3 times daily		250 mg 3 times daily
(patients >65 years)	(150 mg per day)		(750 mg per day)
Renal impairment	50 mg 3 times daily		200 mg 3 times daily
(patients with CrCL	(150 mg per day)		(600 mg per day)
<50 mL per min or end-		In analogo hy no mono	
stage renal disease on		Increase by no more	
dialysis)		than 50 mg 3 times	
Hepatic impairment	50 mg 3 times daily	daily, at weekly intervals	250 mg 3 times daily
(patients with Child-	(150 mg per day)	Intervals	(750 mg per day)
Pugh 7-9)			
Hepatic impairment	50 mg 3 times daily		200 mg 3 times daily
(patients with Child-	(150 mg per day)		(600 mg per day)
Pugh >9)			

24

25 3 DOSAGE FORMS AND STRENGTHS

26 50 mg, purple, round, film-coated tablets debossed with "RTG 50" on one side.

27 200 mg, yellow, oblong, film-coated tablets debossed with "RTG-200" on one side.

28 300 mg, green, oblong, film-coated tablets debossed with "RTG-300" on one side.

29 400 mg, purple, oblong, film-coated tablets debossed with "RTG-400" on one side.

30 4 CONTRAINDICATIONS

31 None.

32 5 WARNINGS AND PRECAUTIONS

33 5.1 Urinary Retention

34 POTIGA caused urinary retention in clinical trials. Urinary retention was generally

35 reported within the first 6 months of treatment, but was also observed later. Urinary retention

36 was reported as an adverse event in 29 of 1,365 (approximately 2%) patients treated with

37 POTIGA in the open-label and placebo-controlled epilepsy database [see Clinical Studies (14)].

38 Of these 29 patients, 5 (17%) required catheterization, with post-voiding residuals of up to

39 1,500 mL. POTIGA was discontinued in 4 patients who required catheterization. Following

- 40 discontinuation, these 4 patients were able to void spontaneously; however, 1 of the 4 patients
- 41 continued intermittent self-catheterization. A fifth patient continued treatment with POTIGA and
- 42 was able to void spontaneously after catheter removal. Hydronephrosis occurred in 2 patients,
- 43 one of whom had associated renal function impairment that resolved upon discontinuation of
- 44 POTIGA. Hydronephrosis was not reported in placebo patients.
- In the placebo-controlled epilepsy trials, "urinary retention," "urinary hesitation," and
 "dysuria" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in
 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.
- Because of the increased risk of urinary retention on POTIGA, urologic symptoms should be carefully monitored. Closer monitoring is recommended for patients who have other risk factors for urinary retention (e.g., benign prostatic hyperplasia [BPH]), patients who are unable to communicate clinical symptoms (e.g., cognitively impaired patients), or patients who use concomitant medications that may affect voiding (e.g., anticholinergics). In these patients, a comprehensive evaluation of urologic symptoms prior to and during treatment with POTIGA
- 54 may be appropriate.

55 **5.2** Neuro-Psychiatric Symptoms

- 56 Confusional state, psychotic symptoms, and hallucinations were reported more frequently 57 as adverse reactions in patients treated with POTIGA than in those treated with placebo in 58 placebo-controlled epilepsy trials (see Table 2). Discontinuations resulting from these reactions 59 were more common in the drug-treated group (see Table 2). These effects were dose-related and 60 generally appeared within the first 8 weeks of treatment. Half of the patients in the controlled 61 trials who discontinued POTIGA due to hallucinations or psychosis required hospitalization. 62 Approximately two-thirds of patients with psychosis in controlled trials had no prior psychiatric history. The psychiatric symptoms in the vast majority of patients in both controlled and open-63 64 label trials resolved within 7 days of discontinuation of POTIGA. Rapid titration at greater than 65 the recommended doses appeared to increase the risk of psychosis and hallucinations.
- 66

67 Table 2. Major Neuro-Psychiatric Symptoms in Placebo-Controlled Epilepsy Trials

	Number (%) With Adverse Reaction		Number (%) D	iscontinuing
	POTIGA	Placebo	POTIGA	Placebo
Adverse Reaction	(n = 813)	(n = 427)	(n = 813)	(n = 427)
Confusional state	75 (9%)	11 (3%)	32 (4%)	4 (<1%)
Psychosis	9 (1%)	0	6 (<1%)	0
Hallucinations ^a	14 (2%)	2 (<1%)	6 (<1%)	0

^a Hallucinations includes visual, auditory, and mixed hallucinations.

69

70 **5.3 Dizziness and Somnolence**

- 71 POTIGA causes dose-related increases in dizziness and somnolence [see Adverse
- 72 *Reactions (6.1)].* In placebo-controlled trials in patients with epilepsy, dizziness was reported in
- 73 23% of patients treated with POTIGA and 9% of patients treated with placebo. Somnolence was

- reported in 22% of patients treated with POTIGA and 12% of patients treated with placebo. In
- these trials 6% of patients on POTIGA and 1.2% on placebo discontinued treatment because of
- 76 dizziness; 3% of patients on POTIGA and <1.0% on placebo discontinued because of
- 77 somnolence.
- 78 Most of these adverse reactions were mild to moderate in intensity and occurred during
- 79 the titration phase. For those patients continued on POTIGA, dizziness and somnolence appeared
- 80 to diminish with continued use.

81 5.4 QT Interval Effect

A study of cardiac conduction showed that POTIGA produced a mean 7.7-msec QT prolongation in healthy volunteers titrated to 400 mg 3 times daily. The QT-prolonging effect occurred within 3 hours. The QT interval should be monitored when POTIGA is prescribed with medicines known to increase QT interval and in patients with known prolonged QT interval, congestive heart failure, ventricular hypertrophy, hypokalemia, or hypomagnesemia [see Clinical *Pharmacology* (12.2)].

88 5.5 Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including POTIGA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

- 93 Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive-therapy) 94 of 11 different AEDs showed that patients randomized to one of the AEDs had approximately 95 twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal 96 thinking or behavior compared to patients randomized to placebo. In these trials, which had a 97 median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation 98 among 27,863 AED-treated patients was 0.43% compared to 0.24% among 16,029 placebo-99 treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior 100 for every 530 patients treated. There were 4 suicides in drug-treated patients in the trials and 101 none in placebo-treated patients, but the number is too small to allow any conclusion about drug 102 effect on suicide. 103 The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1
- 104 week after starting treatment with AEDs and persisted for the duration of treatment assessed.
- Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidalthoughts or behavior beyond 24 weeks could not be assessed.
- 107 The risk of suicidal thoughts or behavior was generally consistent among drugs in the 108 data analyzed. The finding of increased risk with AEDs of varying mechanism of action and 109 comes a more of indications success that the risk applies to all AEDs used for any indication
- across a range of indications suggests that the risk applies to all AEDs used for any indication.
- 110 The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.
- 111 Table 3 shows absolute and relative risk by indication for all evaluated AEDs.
- 112

113 Table 3. Risk of Suicidal Thoughts or Behaviors by Indication for Antiepileptic Drugs in

114 the Pooled Analysis

			Relative Risk:	Risk Difference:
			Incidence of Events in	Additional Drug
	Placebo Patients	Drug Patients	Drug Patients/	Patients With
	With Events per	With Events per	Incidence in Placebo	Events per 1,000
Indication	1,000 Patients	1,000 Patients	Patients	Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

115

116 The relative risk for suicidal thoughts or behavior was higher in clinical trials in patients 117 with epilepsy than in clinical trials in patients with psychiatric or other conditions, but the 118 absolute risk differences were similar for epilepsy and psychiatric indications.

119 Anyone considering prescribing POTIGA or any other AED must balance this risk with 120 the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed 121 are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts 122 and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber 123 needs to consider whether the emergence of these symptoms in any given patient may be related 124 to the illness being treated.

125 Patients, their caregivers, and families should be informed that AEDs increase the risk of 126 suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or 127 worsening of the signs and symptoms of depression; any unusual changes in mood or behavior; 128 or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of

129 concern should be reported immediately to healthcare providers.

130 5.6 Withdrawal Seizures

131 As with all AEDs, when POTIGA is discontinued, it should be withdrawn gradually 132 when possible to minimize the potential of increased seizure frequency [see Dosage and

- 133 Administration (2)]. The dosage of POTIGA should be reduced over a period of at least 3 weeks,
- 134 unless safety concerns require abrupt withdrawal.

135 6 ADVERSE REACTIONS

136

The following adverse reactions are described in more detail in the Warnings and

- 137 Precautions section of the label:
- 138 Urinary retention [see Warnings and Precautions (5.1)] •
- 139 Neuro-psychiatric symptoms [see Warnings and Precautions (5.2)] ٠
- 140 Dizziness and somnolence [see Warnings and Precautions (5.3)] •
- 141 QT interval effect [see Warnings and Precautions (5.4)] ٠
- 142 Suicidal behavior and ideation [see Warnings and Precautions (5.5)] ٠

• Withdrawal seizures [see Warnings and Precautions (5.6)]

1446.1Clinical Trials Experience

145Because clinical trials are conducted under widely varying conditions and for varying

146 durations, adverse reaction frequencies observed in the clinical trials of a drug cannot be directly

- 147 compared with frequencies in the clinical trials of another drug and may not reflect the148 frequencies observed in practice.
- POTIGA was administered as adjunctive therapy to 1,365 patients with epilepsy in all
 controlled and uncontrolled clinical studies during the premarketing development. A total of 801

151 patients were treated for at least 6 months, 585 patients were treated for 1 year or longer, and 311

152 patients were treated for at least 2 years.

153 Adverse Reactions Leading to Discontinuation in All Controlled Clinical Studies:

154 In the 3 randomized, double-blind, placebo-controlled studies, 199 of 813 patients (25%)

receiving POTIGA and 45 of 427 patients (11%) receiving placebo discontinued treatment

because of adverse reactions. The most common adverse reactions leading to withdrawal in

patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and sompolence (3%)

158 somnolence (3%).

159 Common Adverse Reactions in All Controlled Clinical Studies: Overall, the most

160 frequently reported adverse reactions in patients receiving POTIGA (\geq 4% and occurring

approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%),

162 confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%),

disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait

164 disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%). In most cases the

- 165 reactions were of mild or moderate intensity.
- 166

167Table 4. Adverse Reaction Incidence in Placebo-Controlled Adjunctive Trials in Adult

168 Patients With Partial Onset Seizures (Adverse reactions in at least 2% of patients treated

169 with POTIGA in any treatment group and numerically more frequent than in the placebo

170 group.)

		POTIGA				
	Placebo	600 mg/day	900 mg/day	1,200 mg/day	All	
Body System/	(N = 427)	(N = 281)	(N = 273)	(N = 259)	(N = 813)	
Adverse Reaction	%	%	%	%	%	
Eye						
Diplopia	2	8	6	7	7	
Blurred vision	2	2	4	10	5	
Gastrointestinal						
Nausea	5	6	6	9	7	
Constipation	1	1	4	5	3	
Dyspepsia	2	3	2	3	2	

NDA 022345/S-001 FDA Approved Labeling Text dated 3/19/2012 Page 8

General					
Fatigue	6	16	15	13	15
Asthenia	2	4	6	4	5
Infections and infestations					
Influenza	2	4	1	5	3
Investigations					
Weight increased	1	2	3	3	3
Nervous system					
Dizziness	9	15	23	32	23
Somnolence	12	15	25	27	22
Memory impairment	3	3	6	9	6
Tremor	3	3	10	12	8
Vertigo	2	8	8	9	8
Abnormal coordination	3	5	5	12	7
Disturbance in attention	<1	6	6	7	6
Gait disturbance	1	2	5	6	4
Aphasia	<1	1	3	7	4
Dysarthria	<1	4	2	8	4
Balance disorder	<1	3	3	5	4
Paresthesia	2	3	2	5	3
Amnesia	<1	<1	3	3	2
Dysphasia	<1	1	1	3	2
Psychiatric					
Confusional state	3	4	8	16	9
Anxiety	2	3	2	5	3
Disorientation	<1	<1	<1	5	2
Psychotic disorder	0	0	<1	2	<1
Renal and urinary					
Dysuria	<1	1	2	4	2
Urinary hesitation	<1	2	1	4	2
Hematuria	<1	2	1	2	2
Chromaturia	<1	<1	2	3	2

¹⁷¹

172 Other adverse reactions reported in these 3 studies in <2% of patients treated with

173 POTIGA and numerically greater than placebo were increased appetite, hallucinations,

174 myoclonus, peripheral edema, hypokinesia, dry mouth, dysphagia, hyperhydrosis, urinary

175 retention, malaise, and increased liver enzymes.

176 Most of the adverse reactions appear to be dose related (especially those classified as

177 psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state,

178 tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia,

- 179 balance disorder, constipation, dysuria, and chromaturia.
- 180 POTIGA was associated with dose-related weight gain, with mean weight increasing by
- 181 0.2 kg, 1.2 kg, 1.6 kg, and 2.7 kg in the placebo, 600 mg per day, 900 mg per day, and 1,200 mg
- 182 per day groups, respectively.
- 183 Additional Adverse Reactions Observed During All Phase 2 and 3 Clinical Trials:
- 184 Following is a list of adverse reactions reported by patients treated with POTIGA during all
- 185 clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis,
- 186 syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.
- 187 <u>Comparison of Gender, Age, and Race:</u> The overall adverse reaction profile of
 188 POTIGA was similar for females and males.
- 189 There are insufficient data to support meaningful analyses of adverse reactions by age or 190 race. Approximately 86% of the population studied was Caucasian, and 0.8% of the population 191 was older than 65 years.
- 192 7 DRUG INTERACTIONS

193 **7.1** Antiepileptic Drugs

- The potentially significant interactions between POTIGA and concomitant AEDs are summarized in Table 5.
- 196

197 Table 5. Significant Interactions Between POTIGA and Concomitant Antiepileptic Drugs

-					
	Dose of	Dose of	Influence of	Influence of	
	AED	POTIGA	POTIGA on	AED on	
AED	(mg/day)	(mg/day)	AED	POTIGA	Dosage Adjustment
Carbamazepine ^{a,b}	600-	300-1,200	None	31% decrease	consider an increase
	2,400			in AUC,	in dosage of
				23% decrease	POTIGA when
				in C _{max}	adding
					carbamazepine ^c
Phenytoin ^{a,b}	120-600	300-1,200	None	34% decrease	consider an increase
				in AUC,	in dosage of
				18% decrease	POTIGA when
				in C _{max}	adding phenytoin ^c

- ^a Based on results of a Phase 2 study.
- ^b Inducer for uridine 5'-diphosphate (UDP)-glucuronyltransferases (UGTs).
- ^c A decrease in dosage of POTIGA should be considered when carbamazepine or phenytoin is
- 201 discontinued.
- 202 [See Clinical Pharmacology (12.3)]
- 203

204 **7.2 Digoxin**

Data from an *in vitro* study showed that the N-acetyl metabolite of ezogabine (NAMR) inhibited P-glycoprotein-mediated transport of digoxin in a concentration-dependent manner, indicating that NAMR may inhibit renal clearance of digoxin. Administration of POTIGA at therapeutic doses may increase digoxin serum concentrations. Serum levels of digoxin should be

209 monitored [see Clinical Pharmacology (12.3)].

210 **7.3 Alcohol**

Alcohol increased systemic exposure to POTIGA. Patients should be advised of possible worsening of ezogabine's general dose-related adverse reactions if they take POTIGA with alcohol [see Clinical Pharmacology (12.3)].

214 **7.4 Laboratory Tests**

Ezogabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings.

217 8 USE IN SPECIFIC POPULATIONS

218 8.1 Pregnancy

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant
women. POTIGA should be used during pregnancy only if the potential benefit justifies the
potential risk to the fetus.

In animal studies, doses associated with maternal plasma exposures (AUC) to ezogabine and its major circulating metabolite, NAMR, similar to or below those expected in humans at the maximum recommended human dose (MRHD) of 1,200 mg per day produced developmental toxicity when administered to pregnant rats and rabbits. The maximum doses evaluated were

226 limited by maternal toxicity (acute neurotoxicity).

- Treatment of pregnant rats with ezogabine (oral doses of up to 46 mg/kg/day) throughout organogenesis increased the incidences of fetal skeletal variations. The no-effect dose for
- embryo-fetal toxicity in rats (21 mg/kg/day) was associated with maternal plasma exposures
- 230 (AUC) to ezogabine and NAMR less than those in humans at the MRHD. Treatment of pregnant
- rabbits with ezogabine (oral doses of up to 60 mg/kg/day) throughout organogenesis resulted in
- decreased fetal body weights and increased incidences of fetal skeletal variations. The no-effect
- dose for embryo-fetal toxicity in rabbits (12 mg/kg/day) was associated with maternal plasma
- exposures to ezogabine and NAMR less than those in humans at the MRHD.
- Administration of ezogabine (oral doses of up to 61.9 mg/kg/day) to rats throughout pregnancy and lactation resulted in increased pre- and postnatal mortality, decreased body weight gain, and delayed reflex development in the offspring. The no-effect dose for pre- and postnatal developmental effects in rats (17.8 mg/kg/day) was associated with maternal plasma exposures to ezogabine and NAMR less than those in humans at the MRHD.
- 240 <u>Pregnancy Registry:</u> To provide information regarding the effects of *in utero* exposure
 241 to POTIGA, physicians are advised to recommend that pregnant patients taking POTIGA enroll
- 242 in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by

- 243 calling the toll-free number 1-888-233-2334, and must be done by patients themselves.
- 244 Information on the registry can also be found at the website www.aedpregnancyregistry.org.
- 245 8.2 Labor and Delivery
 - The effects of POTIGA on labor and delivery in humans are unknown.

247 8.3 **Nursing Mothers**

246

- 248 It is not known whether ezogabine is excreted in human milk. However, ezogabine and/or 249 its metabolites are present in the milk of lactating rats. Because of the potential for serious
- 250 adverse reactions in nursing infants from POTIGA, a decision should be made whether to
- 251 discontinue nursing or to discontinue the drug, taking into account the importance of the drug to 252 the mother.
- 253 8.4 Pediatric Use
- 254 The safety and effectiveness of POTIGA in patients under 18 years of age have not been 255 established.

256 In juvenile animal studies, increased sensitivity to acute neurotoxicity and urinary bladder 257 toxicity was observed in young rats compared to adults. In studies in which rats were dosed 258 starting on postnatal day 7, ezogabine-related mortality, clinical signs of neurotoxicity, and renal 259 and urinary tract toxicities were observed at doses $\geq 2 \text{ mg/kg/day}$. The no-effect level was 260 associated with plasma ezogabine exposures (AUC) less than those expected in human adults at 261 the MRHD of 1,200 mg per day. In studies in which dosing began on postnatal day 28, acute 262 central nervous system effects, but no apparent renal or urinary tract effects, were observed at 263 doses of up to 30 mg/kg/day. These doses were associated with plasma ezogabine exposures less 264 than those achieved clinically at the MRHD. 265

8.5 **Geriatric Use**

266 There were insufficient numbers of elderly patients enrolled in partial-onset seizure 267 controlled trials (n = 8 patients on ezogabine) to determine the safety and efficacy of POTIGA in 268 this population. Dosage adjustment is recommended in patients aged 65 years and older *[see* 269 Dosage and Administration (2), Clinical Pharmacology (12.3)].

- 270 POTIGA may cause urinary retention. Elderly men with symptomatic BPH may be at 271 increased risk for urinary retention.
- 272 8.6 **Patients With Renal Impairment**
- 273 Dosage adjustment is recommended for patients with creatinine clearance <50 mL/min or 274 patients with end-stage renal disease (ESRD) receiving dialysis treatments [see Dosage and 275 Administration (2), Clinical Pharmacology (12.3)].

276 8.7 **Patients With Hepatic Impairment**

- 277 No dosage adjustment is required for patients with mild hepatic impairment.
- 278 In patients with moderate or severe hepatic impairment, the initial and maintenance
- 279 dosage of POTIGA should be reduced [see Dosage and Administration (2), Clinical
- 280 Pharmacology (12.3)].

281 9 DRUG ABUSE AND DEPENDENCE

282 **9.1 Controlled Substance**

POTIGA is a Schedule V controlled substance.

284 **9.2 Abuse**

283

285 A human abuse potential study was conducted in recreational sedative-hypnotic abusers 286 (n = 36) in which single oral doses of ezogabine (300 mg [n = 33], 600 mg [n = 34], 900 mg 287 [n = 6]), the sedative-hypnotic alprazolam (1.5 mg and 3.0 mg), and placebo were administered. 288 Euphoria-type subjective responses to the 300-mg and 600-mg doses of ezogabine were 289 statistically different from placebo but statistically indistinguishable from those produced by 290 either dose of alprazolam. Adverse events reported following administration of single oral doses 291 of 300 mg, 600 mg, and 900 mg ezogabine given without titration included euphoric mood (18%, 292 21%, and 33%, respectively; 8% from placebo), hallucination (0%, 0%, and 17%, respectively; 293 0% from placebo) and somnolence (18%, 15%, and 67%, respectively; 15% from placebo). 294 In Phase 1 clinical studies, healthy individuals who received oral ezogabine (200 mg to 295 1,650 mg) reported euphoria (8.5%), feeling drunk (5.5%), hallucination (5.1%), disorientation

296 (1.7%), and feeling abnormal (1.5%).

In the 3 randomized, double-blind, placebo-controlled Phase 2 and 3 clinical studies, patients with partial seizures who received oral ezogabine (300 mg to 1,200 mg) reported euphoric mood (0.5%) and feeling drunk (0.9%), while those who received placebo did not report either adverse event (0%).

301 9.3 Dependence

There are no adequate data to assess the ability of ezogabine to induce symptoms of withdrawal indicative of physical dependence. However, the ability of ezogabine to produce psychological dependence is suggested by adverse event reports of euphoric mood (18% [6 of 33 subjects] to 33% [2 of 6 subjects]) in sedative-hypnotic abusers in the human abuse potential study and adverse event reports of euphoria (8.5%) in healthy individuals who participated in Phase 1 studies.

308 10 OVERDOSAGE

309 10.1 Signs, Symptoms, and Laboratory Findings

There is limited experience of overdose with POTIGA. Total daily doses of POTIGA over 2,500 mg were reported during clinical trials. In addition to adverse reactions seen at therapeutic doses, symptoms reported with POTIGA overdose included agitation, aggressive behavior, and irritability. There were no reported sequelae.

In an abuse potential study, cardiac arrhythmia (asystole or ventricular tachycardia) occurred in 2 volunteers within 3 hours of receiving a single 900-mg dose of POTIGA. The arrhythmias spontaneously resolved and both volunteers recovered without sequelae.


- 317 **10.2 Management of Overdose**
- 318 There is no specific antidote for overdose with POTIGA. In the event of overdose,
- 319 standard medical practice for the management of any overdose should be used. An adequate

NDA 022345/S-001 FDA Approved Labeling Text dated 3/19/2012 Page 13


- 320 airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm and vital
- 321 sign measurement is recommended. A certified poison control center should be contacted for
- 322 updated information on the management of overdose with POTIGA.

323 11 DESCRIPTION

The chemical name of ezogabine is N-[2-amino-4-(4-fluorobenzylamino)-phenyl] carbamic acid ethyl ester, and it has the following structure:



326



- POTIGA is supplied for oral administration as 50-mg, 200-mg, 300-mg, and 400-mg
 film-coated immediate-release tablets. Each tablet contains the labeled amount of ezogabine and
 the following inactive ingredients: carmine (50-mg and 400-mg tablets), croscarmellose sodium,
 FD&C Blue No. 2 (50-mg, 300-mg, and 400-mg tablets), hypromellose, iron oxide yellow
 (200-mg and 300-mg tablets), lecithin, magnesium stearate, microcrystalline cellulose, polyvinyl
- alcohol, talc, titanium dioxide, and xanthan gum.

338 12 CLINICAL PHARMACOLOGY

339 12.1 Mechanism of Action

The mechanism by which ezogabine exerts its therapeutic effects has not been fully elucidated. *In vitro* studies indicate that ezogabine enhances transmembrane potassium currents mediated by the KCNQ (Kv7.2 to 7.5) family of ion channels. By activating KCNQ channels, ezogabine is thought to stabilize the resting membrane potential and reduce brain excitability. *In vitro* studies suggest that ezogabine may also exert therapeutic effects through augmentation of GABA-mediated currents.

346 **12.2 Pharmacodynamics**

- The QTc prolongation risk of POTIGA was evaluated in healthy subjects. In a randomized, double-blind, active- and placebo-controlled parallel-group study, 120 healthy subjects (40 in each group) were administered POTIGA titrated up to the final dose of 400 mg 3 times daily, placebo, and placebo and moxifloxacin (on day 22). After 22 days of dosing, the maximum mean (upper 1-sided, 95% CI) increase of baseline- and placebo-adjusted QTc interval
- based on Fridericia correction method (QTcF) was 7.7 msec (11.9 msec) and was observed at 3
- hours after dosing in subjects who achieved 1,200 mg per day. No effects on heart rate, PR, or
- 354 QRS intervals were noted.

- 355 Patients who are prescribed POTIGA with medicines known to increase QT interval or 356 who have known prolonged QT interval, congestive heart failure, ventricular hypertrophy,
- hypokalemia, or hypomagnesemia should be observed closely [see Warnings and Precautions
 (5.4)].
- 359 12.3 Pharmacokinetics
- The pharmacokinetic profile is approximately linear in daily doses between 600 mg and 1,200 mg in patients with epilepsy, with no unexpected accumulation following repeated administration. The pharmacokinetics of ezogabine are similar in healthy volunteers and patients with epilepsy.
- 364 <u>Absorption:</u> After both single and multiple oral doses, ezogabine is rapidly absorbed 365 with median time to maximum plasma concentration (T_{max}) values generally between 0.5 and 2 366 hours. Absolute oral bioavailability of ezogabine relative to an intravenous dose of ezogabine is 367 approximately 60%. High-fat food does not affect the extent to which ezogabine is absorbed 368 based on plasma AUC values, but it increases peak concentration (C_{max}) by approximately 38% 369 and delays T_{max} by 0.75 hour.
- 370 P

POTIGA can be taken with or without food.

<u>Distribution:</u> Data from *in vitro* studies indicate that ezogabine and NAMR are
 approximately 80% and 45% bound to plasma protein, respectively. Clinically significant
 interactions with other drugs through displacement from proteins are not anticipated. The steady state volume of distribution of ezogabine is 2 to 3 L/kg following intravenous dosing, suggesting
 that ezogabine is well distributed in the body.

376 Metabolism: Ezogabine is extensively metabolized primarily via glucuronidation and 377 acetylation in humans. A substantial fraction of the ezogabine dose is converted to inactive N-378 glucuronides, the predominant circulating metabolites in humans. Ezogabine is also metabolized 379 to NAMR that is also subsequently glucuronidated. NAMR has antiepileptic activity, but it is 380 less potent than ezogabine in animal seizure models. Additional minor metabolites of ezogabine 381 are an N-glucoside of ezogabine and a cyclized metabolite believed to be formed from NAMR. 382 In vitro studies using human biomaterials showed that the N-acetylation of ezogabine was 383 primarily carried out by NAT2, while glucuronidation was primarily carried out by UGT1A4, 384 with contributions by UGT1A1, UGT1A3, and UGT1A9.

In vitro studies showed no evidence of oxidative metabolism of ezogabine or NAMR by cytochrome P450 enzymes. Coadministration of ezogabine with medications that are inhibitors or inducers of cytochrome P450 enzymes is therefore unlikely to affect the pharmacokinetics of ezogabine or NAMR.

- 389 <u>Elimination:</u> Results of a mass balance study suggest that renal excretion is the major
- 390 route of elimination for ezogabine and NAMR. About 85% of the dose was recovered in the
- urine, with the unchanged parent drug and NAMR accounting for 36% and 18% of the
- 392 administered dose, respectively, and the total N-glucuronides of ezogabine and NAMR
- 393 accounting for 24% of the administered dose. Approximately 14% of the radioactivity was

- 394 recovered in the feces, with unchanged ezogabine accounting for 3% of the total dose. Average 395 total recovery in both urine and feces within 240 hours after dosing is approximately 98%.
- 396 Ezogabine and its N-acetyl metabolite have similar elimination half-lives $(t_{1/2})$ of 7 to 11 397 hours. The clearance of ezogabine following intravenous dosing was approximately 0.4 to 398 0.6 L/hr/kg. Ezogabine is actively secreted into the urine.
- 399 Specific Populations: Race: No study has been conducted to investigate the impact of 400 race on pharmacokinetics of ezogabine. A population pharmacokinetic analysis comparing 401 Caucasians and non-Caucasians (predominately African American and Hispanic patients) 402 showed no significant pharmacokinetic difference. No adjustment of the ezogabine dose for race 403 is recommended.

404 Gender: The impact of gender on the pharmacokinetics of ezogabine was examined 405 following a single dose of POTIGA to healthy young (aged 21 to 40 years) and elderly (aged 66 406 to 82 years) subjects. The AUC values were approximately 20% higher in young females 407 compared to young males and approximately 30% higher in elderly females compared to elderly 408 males. The C_{max} values were approximately 50% higher in young females compared to young 409 males and approximately 100% higher in elderly females compared to elderly males. There was 410 no gender difference in weight-normalized clearance. Overall, no adjustment of the dosage of 411 POTIGA is recommended based on gender.

412 413

Pediatric Patients: The pharmacokinetics of ezogabine in pediatric patients have not been investigated.

414 Geriatric: The impact of age on the pharmacokinetics of ezogabine was examined 415 following a single dose of ezogabine to healthy young (aged 21 to 40 years) and elderly (aged 66 416 to 82 years) subjects. Systemic exposure (AUC) of ezogabine was approximately 40% to 50% 417 higher and terminal half-life was prolonged by approximately 30% in the elderly compared to the 418 younger subjects. The peak concentration (C_{max}) was similar to that observed in younger 419 subjects. A dosage reduction in the elderly is recommended [see Dosage and Administration (2), 420 Use in Specific Populations (8.5)].

421 Renal Impairment: The pharmacokinetics of ezogabine were studied following a 422 single 100-mg dose of POTIGA in subjects with normal (CrCL >80 ml/min), mild (CrCL \geq 50 to 423 <80 mL/min), moderate (CrCL >30 to <50 mL/min), or severe renal impairment (CrCL <30

- 424 mL/min) (n = 6 in each cohort) and in subjects with ESRD requiring hemodialysis (n = 6). The
- 425 ezogabine AUC was increased by approximately 30% in patients with mild renal impairment and
- 426 doubled in patients with moderate impairment to ESRD (CrCL <50 mL/min) relative to healthy
- 427 subjects. Similar increases in NAMR exposure were observed in the various degrees of renal
- 428 impairment. The effect of hemodialysis on ezogabine clearance has not been established. Dosage
- 429 reduction is recommended for patients with creatinine clearance <50 mL/min and for patients
- 430 with ESRD receiving dialysis [see Dosage and Administration (2), Use in Specific Populations 431 (8.6)].
- 432 Hepatic Impairment: The pharmacokinetics of ezogabine were studied following a 433 single 100-mg dose of POTIGA in subjects with normal, mild (Child-Pugh score 5 to 6),

- 434 moderate (Child-Pugh score 7 to 9), or severe hepatic (Child-Pugh score >9) impairment (n = 6
- 435 in each cohort). Relative to healthy subjects, ezogabine AUC was not affected by mild hepatic
- 436 impairment, but was increased by approximately 50% in subjects with moderate hepatic
- 437 impairment and doubled in subjects with severe hepatic impairment. There was an increase of
- 438 approximately 30% in exposure to NAMR in patients with moderate to severe impairment.
- 439 Dosage reduction is recommended for patients with moderate and severe hepatic impairment
- 440 [see Dosage and Administration (2), Use in Specific Populations (8.7)].
- 441 Drug Interactions: *In vitro* studies using human liver microsomes indicated that
- 442 ezogabine does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2C8, CYP2C9,
- 443 CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5. Inhibition of CYP2B6 by ezogabine has not
- 444 been evaluated. In addition, *in vitro* studies in human primary hepatocytes showed that
- ezogabine and NAMR did not induce CYP1A2 or CYP3A4/5 activity. Therefore, ezogabine is
- 446 unlikely to affect the pharmacokinetics of substrates of the major cytochrome P450 isoenzymes
- 447 through inhibition or induction mechanisms.
- 448 Ezogabine is neither a substrate nor an inhibitor of P-glycoprotein, an efflux transporter.
- 449 NAMR is a P-glycoprotein inhibitor. Data from an *in vitro* study showed that NAMR inhibited
- 450 P-glycoprotein-mediated transport of digoxin in a concentration-dependent manner, indicating
- 451 that NAMR may inhibit renal clearance of digoxin. Administration of POTIGA at therapeutic
- 452 doses may increase digoxin serum concentrations [see Drug Interactions (7.2)].
- 453 *Interactions with Antiepileptic Drugs:* The interactions between POTIGA and
- 454 concomitant AEDs are summarized in Table 6.
- 455

456 **Table 6. Interactions Between POTIGA and Concomitant Antiepileptic Drugs**

	Dose of	Dose of	Influence of	Influence of	
	AED	POTIGA	POTIGA on	AED on	Dosage
AED	(mg/day)	(mg/day)	AED	POTIGA	Adjustment
Carbamazepine ^{a,b}	600-2,400	300-1,200	None	31% decrease	consider an
				in AUC,	increase in
				23% decrease	dosage of
				in C _{max,}	POTIGA when
				28% increase	adding
				in clearance	carbamazepine ^c
Phenytoin ^{a,b}	120-600	300-1,200	None	34% decrease	consider an
				in AUC,	increase in
				18% decrease	dosage of
				in C _{max} ,	POTIGA when
				33% increase	adding
				in clearance	phenytoin ^c
Topiramate ^a	250-1,200	300-1,200	None	None	None
Valproate ^a	750-2,250	300-1,200	None	None	None
Phenobarbital	90	600	None	None	None
Lamotrigine	200	600	18% decrease	None	None

			-				
				in AUC,			
				22% increase			
				in clearance			
	Others ^d			None	None	None	
457	^a Based on results	of a Phase 2 s	tudy.				
458	^b Inducer for uridi	ne 5'-diphosph	nate (UDP)-gl	ucuronyltransfer	ases (UGTs).		
459	^c A decrease in do	se of POTIGA	should be co	onsidered when c	arbamazepine or	phenytoin is	
460	discontinued.						
461	^d Zonisamide, val	proic acid, clor	nazepam, gab	apentin, levetirac	etam, oxcarbaze	pine,	
462	phenobarbital, pr	egabalin, topi	ramate, cloba	zam, and lamotri	gine, based on a	population	
463	pharmacokinetic	analysis using	g pooled data	from Phase 3 clin	nical trials.		
464							
465	Oral Co	ontraceptives	In one study	examining the p	otential interaction	on between	
466	ezogabine (150 mg	g 3 times daily	for 3 days) a	nd the combinati	on oral contracep	otive	
467	norgestrel/ethinyl	estradiol (0.3 r	mg/0.03 mg)	tablets in 20 heal	thy females, no s	ignificant	
468	alteration in the ph	armacokinetic	s of either dr	ug was observed.			
469	In a second	l study examin	ing the poten	tial interaction of	f repeated ezogał	oine dosing	
470	(250 mg 3 times da	aily for 14 day	s) and the co	mbination oral co	ontraceptive nore	thindrone/ethinyl	
471	estradiol (1 mg/0.0	035 mg) tablets	s in 25 health	y females, no sig	nificant alteration	n in the	
472	pharmacokinetics	of either drug	was observed	l.			
473	Alcohol	In a healthy	volunteer stud	ly, the coadminis	tration of ethano	l 1g/kg (5	
474	standard alcohol drinks) over 20 minutes and ezogabine (200 mg) resulted in an increase in the						
475	ezogabine C _{max} and	d AUC by 23%	% and 37%, re	espectively [see]	Drug Interactions	s (7.3)].	
476	13 NONCLIN	IICAL TOXIC	OLOGY				
477	13.1 Carcinog	enesis, Muta	agenesis, In	npairment of F	ertility		
478	<u>Carcinoge</u>	<u>nesis:</u> In a or	e-year neona	tal mouse study of	of ezogabine (2 s	ingle-dose oral	
479	administrations of	up to 96 mg/k	g on postnata	l days 8 and 15),	a dose-related in	crease in the	
480	frequency of lung	neoplasms (br	onchioalveola	ar carcinoma and	/or adenoma) wa	s observed in	
481	treated males. No		••••		0		
482	of ezogabine (oral gavage doses of up to 50 mg/kg/day) for 2 years. Plasma exposure (AUC) to						
483	ezogabine at the highest doses tested was less than that in humans at the maximum						
484	recommended human dose (MRHD) of 1,200 mg per day.						
485	Mutagenesis: Highly purified ezogabine was negative in the <i>in vitro</i> Ames assay, the <i>in</i>						
486	vitro Chinese hamster ovary (CHO) Hprt gene mutation assay, and the in vivo mouse						
487	micronucleus assay. Ezogabine was positive in the in vitro chromosomal aberration assay in						
488	human lymphocytes. The major circulating metabolite of ezogabine, NAMR, was negative in the						
489	in vitro Ames assa						
490			-	ad no effect on fe		-	
491	performance, or ea	rly embryonic	e developmen	t when administe	red to male and f	emale rats at	

doses of up to 46.4 mg/kg/day (associated with a plasma ezogabine exposure [AUC] less than

that in humans at the MRHD) prior to and during mating, and continuing in females through

494 gestation day 7.

49514CLINICAL STUDIES

The efficacy of POTIGA as adjunctive therapy in partial-onset seizures was established
in 3 multicenter, randomized, double-blind, placebo-controlled studies in 1,239 adult patients.
The primary endpoint consisted of the percent change in seizure frequency from baseline in the
double-blind treatment phase.

500 Patients enrolled in the studies had partial onset seizures with or without secondary 501 generalization and were not adequately controlled with 1 to 3 concomitant AEDs, with or 502 without concomitant vagus nerve stimulation. More than 75% of patients were taking 2 or more 503 concomitant AEDs. During an 8-week baseline period, patients experienced at least 4 partial 504 onset seizures per 28 days on average with no seizure-free period exceeding 3 to 4 weeks. 505 Patients had a mean duration of epilepsy of 22 years. Across the 3 studies, the median baseline 506 seizure frequency ranged from 8 to 12 seizures per month. The criteria for statistical significance 507 was *P*<0.05. 508 Patients were randomized to the total daily maintenance dosages of 600 mg per day,

509 900 mg per day, or 1,200 mg per day, each administered in 3 equally divided doses. During the

- 510 titration phase of all 3 studies, treatment was initiated at 300 mg per day (100 mg 3 times per
- 511 day) and increased in weekly increments of 150 mg per day to the target maintenance dosage.

512 Figure 1 shows the median percent reduction in 28-day seizure frequency (baseline to


513 double-blind phase) as compared with placebo across all 3 studies. A statistically significant

effect was observed with POTIGA at doses of 600 mg per day (Study 1), at 900 mg per day

- 515 (Studies 1 and 3), and at 1,200 mg per day (Studies 2 and 3).
- 516

NDA 022345/S-001 FDA Approved Labeling Text dated 3/19/2012 Page 19





519 520


Figure 2 shows changes from baseline in the 28-day total partial seizure frequency by category for patients treated with POTIGA and placebo in an integrated analysis across the 3 clinical trials. Patients in whom the seizure frequency increased are shown at left as "worse."

524 Patients in whom the seizure frequency decreased are shown in five categories.

525

526 Figure 2. Proportion of Patients by Category of Seizure Response for POTIGA

527 and Placebo Across All Three Double-blind Trials



528

529 16 HOW SUPPLIED/STORAGE AND HANDLING

530 POTIGA is supplied as film-coated immediate-release tablets for oral administration

- 531 containing 50 mg, 200 mg, 300 mg, or 400 mg of ezogabine in the following packs:
- 532 **50-mg Tablets:** purple, round, film-coated tablets debossed with "RTG 50" on one side in
- 533 bottles of 90 with desiccant (NDC 0173-0810-59).
- 534 **200-mg Tablets:** yellow, oblong, film-coated tablets debossed with "RTG-200" on one side in
- bottles of 90 with desiccant (NDC 0173-0812-59).
- 536 **300-mg Tablets:** green, oblong, film-coated tablets debossed with "RTG-300" on one side in
- 537 bottles of 90 with desiccant (NDC 0173-0813-59).
- 538 **400-mg Tablets:** purple, oblong, film-coated tablets debossed with "RTG-400" on one side in
- 539 bottles of 90 with desiccant (NDC 0173-0814-59).
- 540 Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled 541 Room Temperature.]

542 17 PATIENT COUNSELING INFORMATION

- 543 See FDA-approved patient labeling (Medication Guide).
- 544 **17.1 Urinary Retention**

- 545Patients should be informed that POTIGA can cause urinary retention (including urinary
- hesitation and dysuria). If patients experience any symptoms of urinary retention, inability to
- 547 urinate, and/or pain with urination, they should be instructed to seek immediate medical
- 548 assistance [see Warnings and Precautions (5.1)]. For patients who cannot reliably report
- 549 symptoms of urinary retention (for example, patients with cognitive impairment), urologic
- 550 consultation may be helpful.

551 **17.2 Psychiatric Symptoms**

Patients should be informed that POTIGA can cause psychiatric symptoms such as
confusional state, disorientation, hallucinations, and other symptoms of psychosis. Patients and
their caregivers should be instructed to notify their physicians if they experience psychotic
symptoms [see Warnings and Precautions (5.2)].

556 17.3 Central Nervous System Effects

557 Patients should be informed that POTIGA may cause dizziness, somnolence, memory 558 impairment, abnormal coordination/balance, disturbance in attention, and ophthalmological 559 effects such as diplopia or blurred vision. Patients taking POTIGA should be advised not to 560 drive, operate complex machinery, or engage in other hazardous activities until they have 561 become accustomed to any such effects associated with POTIGA [see Warnings and Precautions 562 (5.3)].

563 17.4 Suicidal Thinking and Behavior

Patients, their caregivers, and families should be informed that AEDs, including POTIGA, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about selfharm. Behaviors of concern should be reported immediately to healthcare providers *[see Warnings and Precautions (5.5)]*.

570 **17.5 Pregnancy**

571 Patients should be advised to notify their physicians if they become pregnant or intend to
572 become pregnant during therapy. Patients should be advised to notify their physicians if they
573 intend to breastfeed or are breastfeeding an infant.

Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they
become pregnant. This registry collects information about the safety of AEDs during pregnancy.
To enroll, patients can call the toll-free number 1-888-233-2334 [see Use in Specific Populations
(8.1)].

- 578
- 579 POTIGA is a trademark of Valeant Pharmaceuticals North America.
- 580
- 581

582





583	Gl	axoSmithKline					
584	Re	search Triangle Park, NC 27709					
585							
586	©2	2012, GlaxoSmithKline. All rights reserved.					
587							
588	Ma	arch 2012					
589	РТ	'G:xPI					
590							
591		MEDICATION GUIDE					
592		POTIGA [™] (po-TEE-ga) Tablets, CV					
593		(ezogabine)					
594							
595	Re	ad this Medication Guide before you start taking POTIGA and each time you get a refill.					
596	Th	ere may be new information. This Medication Guide does not take the place of talking to your					
597	hea	althcare provider about your medical condition or treatment. If you have questions about					
598	PC	TIGA, ask your healthcare provider or pharmacist.					
599							
600	W	hat is the most important information I should know about POTIGA?					
601	Do not stop POTIGA without first talking to a healthcare provider. Stopping POTIGA suddenly						
602	can cause serious problems. Stopping POTIGA suddenly can cause you to have more seizures						
603	mo	ore often.					
604	1.	POTIGA can make it hard for you to urinate (empty your bladder) and may cause you to					
605		be unable to urinate. Call your healthcare provider right away if you:					
606		• are unable to start urinating					
607		• have trouble emptying your bladder					
608		• have a weak urine stream					
609		• have pain with urination					
610	2.	POTIGA can cause mental (psychiatric) problems, including:					
611		 confusion 					
612		• new or worse aggressive behavior, hostility, anger, or irritability					
613		• new or worse psychosis (hearing or seeing things that are not real)					
614		• being suspicious or distrustful (believing things that are not true)					
615		• other unusual or extreme changes in behavior or mood					
616		Tell your healthcare provider right away if you have any new or worsening mental problems					
617		while using POTIGA.					
618 619	3.	Like other antiepileptic drugs, POTIGA may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.					

620	Call a healthcare provider right away if you have any of these symptoms, especially if
621	they are new, worse, or worry you:
622	• thoughts about suicide or dying
623	attempt to commit suicide
624	new or worse depression
625	• new or worse anxiety
626	• feeling agitated or restless
627	• panic attacks
628	• trouble sleeping (insomnia)
629	• new or worse irritability
630	• acting aggressive, being angry, or violent
631	• acting on dangerous impulses
632	• an extreme increase in activity and talking (mania)
633	• other unusual changes in behavior or mood
	C C
634	Suicidal thoughts or actions can be caused by things other than medicines. If you have
635	suicidal thoughts or actions, your healthcare provider may check for other causes.
636	
637	How can I watch for early symptoms of suicidal thoughts and actions?
638	• Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or
639	feelings.
640	• Keep all follow-up visits with your healthcare provider as scheduled.
641 642	Call your healthcare provider between visits as needed, especially if you are worried about symptoms.
643	Do not stop POTIGA without first talking to a healthcare provider.
644	Stopping POTIGA suddenly can cause serious problems. Stopping POTIGA suddenly can cause
645	you to have more seizures more often.
646	
647	What is POTIGA?
648	POTIGA is a prescription medicine that is used with other medicines to treat partial onset
649	seizures in people with epilepsy who are 18 years of age or older.
650	POTIGA is a controlled substance (CV) because it can be abused or lead to drug dependence.
651	Keep your POTIGA in a safe place to protect it from theft. Never give your POTIGA to anyone
652	else because it may harm them. Selling or giving away this medicine is against the law.
653	ense securise it muy numit ment. Senting of giving uway this medicine is against the law.
654	It is not known if POTIGA is safe and effective in children under 18 years of age.
655	2
656	What should I tell my healthcare provider before taking POTIGA?
657	Before you take POTIGA, tell your healthcare provider if you:
658	 have trouble urinating
030	

- 659 have an enlarged prostate
- have or have had depression, mood problems, or suicidal thoughts or behavior
- have heart problems, including a condition called long QT Syndrome, or have low potassium
 or magnesium in your blood
- 663 have liver problems
- 664 have kidney problems
- 665 drink alcohol
- have any other medical conditions
- 667 are pregnant or plan to become pregnant. It is not known if POTIGA will harm your unborn
 668 baby.
- If you become pregnant while taking POTIGA, talk to your healthcare provider about
 registering with the North American Antiepileptic Drug Pregnancy Registry. The purpose
 of this registry is to collect information about the safety of medicines used to treat
- 672 seizures during pregnancy. You can enroll in this registry by calling 1-888-233-2334.
- are breastfeeding or plan to breastfeed. It is not known if POTIGA passes into your breast
 milk. Talk to your healthcare provider about the best way to feed your baby if you take
 POTIGA. You and your healthcare provider should decide if you will take POTIGA or
 breastfeed. You should not do both.
- 677 **Tell your healthcare provider about all the medicines you take,** including prescription and 678 non-prescription medicines, vitamins, and herbal supplements. Taking POTIGA with certain
- 679 other medicines can affect each other, causing side effects. **Especially tell your healthcare**
- 680 provider if you take:
- 681 digoxin (LANOXIN[®])
- 682 phenytoin (DILANTIN[®], PHENYTEK[®])
- 683 carbamazepine (CARBATROL[®], TEGRETOL[®], TEGRETOL[®]-XR, EQUETRO[®], EPITOL[®])
- Know the medicines you take. Keep a list of them to show your doctor and pharmacist when youget a new medicine.
- Take POTIGA exactly as your healthcare provider tells you to take it. Your healthcare
 provider will tell you how much POTIGA to take and when to take it.
- Wour healthcare provider may change your dose of POTIGA. Do not change your dose without talking to your healthcare provider.
- POTIGA can be taken with or without food.
- 692 Swallow POTIGA Tablets whole. Do not break, crush, dissolve, or chew POTIGA tablets
 693 before swallowing.
- Talk to your doctor about what to do if you miss one or more doses of POTIGA.
- If you take too much POTIGA, call your local Poison Control Center or go to the nearest
 hospital emergency room right away.

697

NDA 022345/S-001 FDA Approved Labeling Text dated 3/19/2012 Page 25

698 What should I avoid while taking POTIGA?

- 699 Do not drive, operate machinery, or do other dangerous activities until you know how POTIGA
- affects you. POTIGA can cause dizziness, sleepiness, double-vision, and blurred vision.
- 701

702 What are the possible side effects of POTIGA?

703 **POTIGA may cause serious side effects, including:**

- See "What is the most important information I should know about POTIGA?"
- Dizziness and sleepiness. These symptoms can increase when your dose of POTIGA is
 increased. See "What should I avoid while taking POTIGA?"
- 707 Changes in your heart rhythm and the electrical activity of your heart. Your healthcare
 708 provider should monitor your heart during treatment if you have a certain type of heart
 709 disease or take certain medications.
- Drinking alcohol during treatment with POTIGA may increase the side effects that you get
 with POTIGA.
- 712 The most common side effects of POTIGA include:
- 713 dizziness
- 714 somnolence
- 715 sleepiness
- tiredness
- 717 confusion
- 718•spinning sensation (vertigo)
- tremor
- problems with balance and muscle coordination, including trouble with walking and moving
- blurred or double vision
- 722 trouble concentrating
- 723 memory problems
- weakness
- Tell your healthcare provider about any side effect that bothers you or that does not go away.
- These are not all the possible side effects of POTIGA. Ask your healthcare provider or
- 727 pharmacist for more information.
- Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
- 730
- 731 How should I store POTIGA?
- Store POTIGA at room temperature at 59° F to 86° F (15° C to 30° C).
- **Keep POTIGA and all medicines out of the reach of children.**
- 734
- 735 General information about the safe and effective use of POTIGA.

- 736 Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
- 737 Do not use POTIGA for a condition for which it was not prescribed. Do not give POTIGA to
- other people, even if they have the same symptoms you have. It may harm them.
- 739 This Medication Guide summarizes the most important information about POTIGA. If you
- 740 would like more information, talk with your healthcare provider. You can ask your healthcare
- 741 provider or pharmacist for information about POTIGA that is written for healthcare
- 742 professionals.
- For more information, go to www.potiga.com or call 1-888-825-5249.
- 744

745 What are the ingredients in POTIGA?

- 746 Active ingredient: ezogabine.
- 747 Inactive ingredients in all strengths: croscarmellose sodium, hypromellose, lecithin, magnesium
- stearate, microcrystalline cellulose, polyvinyl alcohol, talc, titanium dioxide, and xanthan gum.
- 749 50-mg and 400-mg tablets also contain: carmine.
- 50-mg, 300-mg, and 400-mg tablets also contain: FD&C Blue No 2.
- 751 200-mg and 300-mg tablets also contain: iron oxide yellow.
- 752
- 753 POTIGA is a trademark of Valeant Pharmaceuticals North America.
- 754
- 755 The brands listed are trademarks of their respective owners and are not trademarks of
- 756 GlaxoSmithKline. The makers of these brands are not affiliated with and do not endorse
- 757 GlaxoSmithKline or its products.
- 758
- 759





- 761 GlaxoSmithKline
- 762 Research Triangle Park, NC 27709
- 763

760

- 764 This Medication Guide has been approved by the U.S. Food and Drug Administration.
- 765
- 766 ©2012, GlaxoSmithKline. All rights reserved.
- 767
- 768 March 2012
- 769 PTG:xMG

APPENDIX A – REMS

Initial REMS Approval: 06/10/2011 Most Recent Modification: 03/2012

NDA 22-345 POTIGA[™] (ezogabine) Tablets €

Drug Class: Anticonvulsant

GlaxoSmithKline LLC Corporation Service Company 2711 Centerville Road, Suite 400 Wilmington DE 19808

For correspondence (Authorized US Agent): 5 Moore Drive (MS 5.5222) Research Triangle Park, NC 27709-3398 919-483-3073 Fax: 919-315-8319

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL:

The goal of the REMS for POTIGA is to inform healthcare professionals of the risk of urinary retention and the symptoms of acute urinary retention in patients taking POTIGA.

II. REMS ELEMENTS

A. Communication Plan

For Healthcare Professionals

GlaxoSmithKline LLC (GSK) will implement a communication plan to support the implementation of this REMS that includes the following elements:

1. A Dear Healthcare Professional (HCP) Letter designed to disseminate information about the risk of urinary retention with POTIGA. Within the first four weeks of retail availability of POTIGA, and annually from that date for the next two years, the Dear Healthcare Professional (HCP) letters will be mailed to the following audiences:

- a. Prescribing physicians (i.e., Epileptologists, Neurologists and Neurosurgeons) and physicians who may evaluate and treat patients with possible urinary retention (i.e., Urologists and Emergency Room Physicians)
- b. Pharmacists dispensing POTIGA tablets and the Medication Guide

After the initial mailing, new prescribers of POTIGA will be included in subsequent mailings of the Dear HCP letter.

The mailing will include a copy of the Prescribing Information (PI) and the Medication Guide.

- 2. REMS Program Website
 - a. There are two ways that Healthcare Professionals (HCPs) can access the REMS Program information for POTIGA on the internet. The REMS Program website for HCPs will be accessed directly from the homepage for POTIGA (www.potiga.com) via the "for HCP" link. In addition, this page will automatically be shown when HCPs visit GSK's professional website portal www.gsksource.com and click on product information for POTIGA. This REMS Program information will be shown automatically, such that HCPs visiting the healthcare provider area of the website can view the REMS Program information prior to viewing other areas of the website. Included in the information will be a brief explanation of the REMS, the goal of the REMS for POTIGA, and separate links for downloadable versions of the full Prescribing Information, the Medication Guide, and the Dear HCP Letters. The webpage also includes the indication for POTIGA, Important Safety Information for Healthcare Professionals, and links to other product information for POTIGA.
 - b. The online information will be available to all healthcare professionals as it is in the public domain.

The following materials are part of the REMS and are attached:

- Dear Healthcare Professional Letter (Attachment A)
- Dear Pharmacist Letter (Attachment B)
- REMS Program website for healthcare professionals (Attachment C)

B. Timetable for Submission of Assessments

GSK will submit assessments of the REMS to FDA 1, 2, 3, and 7 years from the date of initial approval of the REMS (June 10, 2011).

To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date for that assessment.

GSK will submit each assessment so it will be received by the FDA on or before the due date.

ATTACHMENT A – Dear Healthcare Professional Letter – Physicians

IMPORTANT DRUG WARNING

Subject: Risk of Urinary Retention with POTIGA

Dear Healthcare Professional

The purpose of this letter is to inform you of important safety information for POTIGATM (ezogabine) Tablets , approved by the Food and Drug Administration (FDA) for adjunctive treatment of partial onset seizures in patients 18 years of age and older. As a potassium channel opener, POTIGA can reduce the contractility of urinary bladder smooth muscle which can cause urinary retention.

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for POTIGA to ensure the benefits of the drug outweigh the risk of urinary retention and its associated morbidities. As one element of the REMS, we are providing this letter to further communicate this risk.

Risk of Urinary Retention

POTIGA caused urinary retention in clinical trials. Urinary retention was reported in 29 of 1365 (approximately 2%) patients receiving POTIGA in open-label and placebo controlled epilepsy trials with 5 (17%) of these patients requiring catheterization for urinary retention. POTIGA was discontinued in 4 patients who required catheterization. Following discontinuation, these 4 patients were able to void spontaneously; however, 1 of the 4 patients continued intermittent self-catheterization. A fifth patient continued treatment with POTIGA and was able to void spontaneously after catheter removal. Hydronephrosis occurred in 2 patients, one of whom had associated renal function impairment that resolved upon discontinuation of POTIGA. Hydronephrosis was not reported in placebo patients. An assessment of a patient's risk of urinary retention, including medical history and concomitant medication use, should be made for all patients before initiating treatment with POTIGA.

The Prescribing Information for POTIGA states in the *Warnings and Precautions* section that because of the increased risk of urinary retention on POTIGA, urologic symptoms should be carefully monitored. Closer monitoring is recommended for patients who have other risk factors for urinary retention (e.g., benign prostatic hyperplasia [BPH]), patients who are unable to communicate clinical symptoms (e.g., cognitively impaired patients), or patients who use concomitant medications that may affect voiding (e.g., anticholinergics). In these patients, a comprehensive evaluation of urologic symptoms prior to and during treatment with POTIGA may be appropriate.

Prescribers should inform all patients that:

- POTIGA may cause urinary retention, including urinary hesitation and dysuria
- Patients should seek immediate medical attention if they experience any symptoms of urinary retention, are unable to urinate and/or have urinary pain

Urologists and Emergency Room Physicians may be asked to evaluate patients with respect to suitability for treatment with POTIGA or to evaluate and/or treat patients with potential urinary retention.

Medication Guide

A Medication Guide is available for POTIGA and contains important safety information for patients. Specifically, the Medication Guide includes information on symptoms of urinary retention described as being unable to start urinating, having trouble emptying the bladder, having a weak urine stream, or having pain with urination. The Medication Guide instructs patients to call their healthcare provider right away if they experience any of these symptoms.

Additional copies of the Medication Guide for POTIGA are available from:

- the toll-free medical information line at 1-888-825-5249
- an informational website for POTIGA: <u>www.potiga.com</u>

Reporting Adverse Events

If you become aware of an adverse event involving POTIGA please contact:

- GlaxoSmithKline at 1-800-334-4153 and/or
- FDA MedWatch program by phone at 1-800-FDA-1088 or online at <u>www.fda.gov/medwatch/report.htm</u>

This letter is not a comprehensive description of the risks with the use of POTIGA. Please read the accompanying full Prescribing Information and Medication Guide for a complete description of these risks.

ATTACHMENT B – Dear Healthcare Professional Letter – Pharmacist

IMPORTANT DRUG WARNING

Subject: Risk of Urinary Retention with POTIGA

Dear Pharmacist

The purpose of this letter is to inform you of important safety information for POTIGATM (ezogabine) Tablets , approved by the Food and Drug Administration (FDA) for adjunctive treatment of partial onset seizures in patients 18 years of age and older. As a potassium channel opener, POTIGA can reduce the contractility of urinary bladder smooth muscle which can cause urinary retention.

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for POTIGA to ensure the benefits of the drug outweigh the risk of urinary retention and its associated morbidities.

As one element of the REMS, we are providing this letter to further communicate these risks.

Risk of Urinary Retention

POTIGA caused urinary retention in clinical trials. The Prescribing Information for POTIGA states in the *Warnings and Precautions* section that because of the increased risk of urinary retention on POTIGA, urologic symptoms should be carefully monitored. Closer monitoring is recommended for patients who have other risk factors for urinary retention (e.g., benign prostatic hyperplasia [BPH]), patients who are unable to communicate clinical symptoms (e.g., cognitively impaired patients), or patients who use concomitant medications that may affect voiding (e.g., anticholinergics).

Patients should be informed that POTIGA may cause urinary retention (including urinary hesitation and dysuria). If patients experience any symptoms of urinary retention, inability to urinate, and/or pain with urination, they should be instructed to seek immediate medical assistance, as these symptoms may indicate possible acute urinary retention.

As a Pharmacist, you have a key role in communicating these risks by providing the Medication Guide with every prescription filled for POTIGA and counselling patients as appropriate.

Medication Guide

A Medication Guide is available for POTIGA and contains important safety information for patients. Specifically, the Medication Guide includes information on symptoms of urinary retention described as being unable to start urinating, having trouble emptying the bladder, having a weak urine stream, or having pain with urination. The Medication Guide instructs patients to call their healthcare provider right away if they experience any of these symptoms.

The Medication Guide will be attached to every bottle and enclosed in each sample pack of POTIGA. The label of each container or package of POTIGA will include a prominent instruction to dispensers to provide a Medication Guide, which is attached to the package. The instruction states "Dispense the accompanying Medication Guide to each patient."

Additional copies of the Medication Guide for POTIGA are available from:

- the toll-free medical information line at 1-888-825-5249
- an informational website for POTIGA: <u>www.potiga.com</u>

Reporting Adverse Events

If you become aware of an adverse event involving POTIGA please contact:

- GlaxoSmithKline at 1-800-334-4153and/or
- FDA MedWatch program by phone at 1-800-FDA-1088 or online at www.fda.gov/medwatch/report.htm

This letter is not a comprehensive description of the risks with the use of POTIGA. Please read the accompanying full Prescribing Information and Medication Guide for a complete description of these risks.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RUSSELL G KATZ 03/19/2012